By October of this year, a small group of New Zealanders living with Motor Neuron Disease will begin their journey as members of the first-ever international phase 3 MND clinical trial to be offered in New Zealand, across multiple locations. The Lighthouse II trial looks at whether human endogenous retroviruses (HERVs) play a role in … Read more
A summary of research from the 2018 Australasian MND Symposium. This information will be of interest to health professionals, people living with MND and their families and carers. This update discusses the importance of quality palliative care throughout the course of MND from all health professionals involved. For an easier to read format, please click here … Read more
A summary of research from the 2018 Australasian MND Symposium. This information will be of interest to neurologists and researchers with an interest in MND, and people affected by MND who have a strong interest in scientific research. This update discusses some key global and Australian clinical trials in 2018, the current issues in clinical … Read more
A summary of research from the 2018 Australasian MND Symposium. This information will be of interest to neurologists and researchers with an interest in MND, and people affected by MND who have a strong interest in scientific research. This update discusses the early 2018 drug development pipeline and our current understanding of the disease mechanisms … Read more
A summary of research from the 2018 Australasian MND Symposium. This information will be of interest to people with MND, their carers and health professionals. Below is a broad update about developments in research towards a cure and understanding the causes of MND, including a proposed staging system for MND (similar to that used for … Read more
Live updates from the Australasian MND Symposium, March 23, 2018. Written by a non-scientist for a layperson audience. This means we’re skipping the complicated science and going straight for the highlights. Typing fast and editing slow, so excuse spelling mistakes. UPDATES FROM AUSTRALIA AND THE WORLD 8:45am Carol Birks (CEO, MND Australia) – 10 years … Read more
Live updates from the Australasian MND Symposium, March 23, 2018. Written by a non-scientist for a layperson audience. This means we’re skipping the complicated science and going straight for the highlights. Typing fast and editing slow, so excuse spelling mistakes. DRUG DEVELOPMENT AND CLINICAL TRIAL DESIGN SESSION 8:30am Dr Lucie Bruijn – Opportunities and Advances … Read more
Live updates from the Australasian MND Symposium, March 22, 2018. Written by a non-scientist for a layperson audience. This means we’re skipping the complicated science and going straight for the highlights. Typing fast and editing slow, so excuse spelling mistakes. The team from MND New Zealand are at the inaugural Australasian MND Symposium hosted by … Read more
The New Zealand MND Registry was launched in May 2017, just 8 months after 4000 participants in the Walk 2 D’Feet MND fundraised to establish the Registry. The New Zealand Motor Neurone Disease Registry was launched on on Monday 22 May 2017, just eight months after 4000 participants in 14 fundraising walks all over New … Read more
Edaravone is not yet available on prescription in New Zealand. MND New Zealand will keep our community informed about further developments and what they may mean for people with MND in New Zealand. This is what we know so far. On Friday 5 May, the US Food and Drug Administration (the FDA) announced its approval … Read more
Another interesting finding in the ongoing hunt for MND treatments comes from University of Tokyo researchers, who have discovered that a safe, existing anti-epileptic drug called perampanel has successfully prevented the death of motor neurons in mice with an animal model of MND. Their research shows that perampanel is worthy of a clinical trial for … Read more
“I’ve never seen a more exciting year,” says Dr Richard Bedlack, top doc at the Duke ALS Clinic in the US. He thinks 2016 is a pivotal year in the fight against MND/ALS, because in just the last year scientists have made a number of potential breakthroughs (greatly due to money brought in by the … Read more